Please note that login will be disabled for maintenance during the period: 13:00 - 14:00 GMT

Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Recent
Upcoming
Share :

1st Immunotherapy of Cancer Conference (ITOC 1)

12 - 14 Mar 2014
TBA, Munich, Germany
Videos

Emerging pathways in immunotherapy

Prof Christopher Höller - Medical University of Vienna, Vienna, Austria
Emerging pathways in immunotherapy ( Prof Christopher Höller - Medical University of Vienna, Vienna, Austria )
20 May 2014

Checkpoint blockade: a concept or already a reality?

Prof Paolo Ascierto - National Cancer Institute 'Foundazione G. Pascale', Naples, Italy
Checkpoint blockade: a concept or already a reality? ( Prof Paolo Ascierto - National Cancer Institute 'Foundazione G. Pascale', Naples, Italy )
20 May 2014

Cancer evasion of the immune system: the fundamentals

Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland
Cancer evasion of the immune system: the fundamentals ( Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland )
20 May 2014

Biomarker development for ipilimumab and prostate GVAX treatment

Prof Tanja D. de Gruijl - VU University Medical Centre, Amsterdam, The Netherlands
Biomarker development for ipilimumab and prostate GVAX treatment ( Prof Tanja D. de Gruijl - VU University Medical Centre, Amsterdam, The Netherlands )
26 Mar 2014

Toll like receptor 7 agonists for cancer immunotherapy

Prof Stefan Endres - Ludwig-Maximilians-Universität, Munich, Germany
Toll like receptor 7 agonists for cancer immunotherapy ( Prof Stefan Endres - Ludwig-Maximilians-Universität, Munich, Germany )
25 Mar 2014

Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703

Prof Jorge Riera-Knorrenschild - University Clinic Giessen and Marburg, Marburg, Germany
Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703 ( Prof Jorge Riera-Knorrenschild - University Clinic Giessen and Marburg, Marburg, Germany )
25 Mar 2014

Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes

Prof Inge Marie Svane - Herlev Hospital, Copenhagen University, Copenhagen, Denmark
Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes ( Prof Inge Marie Svane - Herlev Hospital, Copenhagen University, Copenhagen, Denmark )
25 Mar 2014

The 1st Immunotherapy of Cancer Conference (ITOC)

Prof Heinz Zwierina - Innsbruck Medical University, Innsbruck, Austria
The 1st Immunotherapy of Cancer Conference (ITOC) ( Prof Heinz Zwierina - Innsbruck Medical University, Innsbruck, Austria )
25 Mar 2014

Reasons for combining immunotherapy with chemo to enhance anti tumour response

Prof Angus Dalgleish - St George's, University of London, London, UK
Reasons for combining immunotherapy with chemo to enhance anti tumour response ( Prof Angus Dalgleish - St George's, University of London, London, UK )
25 Mar 2014

High-affinity CD20-specific TCRs suitable for adoptive immunotherapy isolated from the allo-repertoire using reverse immunology

Dr Lorenz Jahn - Leiden Univeristy Medical Centre, Leiden, The Netherlands
High-affinity CD20-specific TCRs suitable for adoptive immunotherapy isolated from the allo-repertoire using reverse immunology ( Dr Lorenz Jahn - Leiden Univeristy Medical Centre, Leiden, The Netherlands )
25 Mar 2014

Molecular pathways associated with immune modulation and thalidomide analogues

Dr Rajesh Chopra - Vice President of Translational and Early Drug Development, Celgene
Molecular pathways associated with immune modulation and thalidomide analogues ( Dr Rajesh Chopra - Vice President of Translational and Early Drug Development, Celgene )
25 Mar 2014

Dendritic cell vaccination combined with CTLA4 blockade

Dr Kris Thielemans - Medical School of the VUB, Brussels, Belgium
Dendritic cell vaccination combined with CTLA4 blockade ( Dr Kris Thielemans - Medical School of the VUB, Brussels, Belgium )
25 Mar 2014

mRNA-based cancer vaccines

Dr Karl-Josef Kallen - Principal Scientific Fellow, CureVac Gmbh
mRNA-based cancer vaccines ( Dr Karl-Josef Kallen - Principal Scientific Fellow, CureVac Gmbh )
24 Mar 2014

Immuno-biological properties of human cancer stem cells

Dr Cristina Maccalli - NIBIT (Italian Network for Biotherapy of Tumours), Siena, Italy
Immuno-biological properties of human cancer stem cells ( Dr Cristina Maccalli - NIBIT (Italian Network for Biotherapy of Tumours), Siena, Italy )
24 Mar 2014

Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer

Dr Christian Klein - Head of Oncology Programs, Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland
Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer ( Dr Christian Klein - Head of Oncology Programs, Discovery Oncology, Roche Pharma Research and Early Development, Roche Glycart AG, Schlieren, Switzerland )
24 Mar 2014

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation